Publications by authors named "Parminder Judge"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

35,532

Total Likes

1,565

Extended Reach

3,280,398

Social Features

334
E
Empagliflozin in Patients with Chronic Kidney Disease.

January 2023

Videos about Article: user user user 5

8 4 11 320 9 89

View All Article and Social Media Activity
E
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.
William G Herrington, Zhaojing J Che, Rebecca Sardell, Alistair J Roddick, Parminder K Judge

Lancet Diabetes Endocrinol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.
Doreen Zhu, Parminder K Judge, Susan T Francis, Zhaojing Che, Jennifer J Rayner

Am J Kidney Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose Interference in Urine Biomarkers and Implications for Sodium-Glucose Cotransporter 2 Inhibition.
Greco B Malijan, Daniel Chapman, Stewart Moffat, Rebecca J Sardell, Natalie Staplin, Parminder K Judge

Kidney Int Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic kidney disease.
William G Herrington, Parminder K Judge, Morgan E Grams, Christoph Wanner

Lancet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.
Greco B Malijan, Rebecca J Sardell, Natalie Staplin, Olivier Devuyst, Daniel Chapman, Parminder K Judge

Am J Kidney Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Junwen Zhou, Claire Williams, Natalie Staplin, Parminder K Judge, Kaitlin J Mayne

EClinicalMedicine· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Parminder K Judge, Katherine R Tuttle, Natalie Staplin, Sibylle J Hauske, Doreen Zhu

Nephrol Dial Transplant· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prevention and management of chronic kidney disease among patients with metabolic syndrome.
Doreen Zhu, Parminder K Judge, Christoph Wanner, Richard Haynes, William G Herrington

Kidney Int· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Kaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, Parminder K Judge, Doreen Zhu

Nephrol Dial Transplant· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

N Engl J Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.
Doreen Zhu, Parminder K Judge, Natalie Staplin, Richard Haynes, William G Herrington

Nephrol Dial Transplant· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Kaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, Parminder K Judge, Doreen Zhu

Clin J Am Soc Nephrol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cohort Profile: Indian Study of Healthy Ageing (ISHA-Barshi).
Sharayu Sitaram Mhatre, Fiona Bragg, Nandkumar Panse, Parminder Kaur Judge, Ankita Manjrekar

Int J Epidemiol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in Kidney Outcomes Over the Years: Reason for Optimism but a Challenge for Trialists.
Doreen Zhu, Parminder K Judge, Richard Haynes

Am J Kidney Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Kaitlin J Mayne, Natalie Staplin, David F Keane, Christoph Wanner, Susanne Brenner, Parminder K Judge

J Am Soc Nephrol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacubitril/valsartan in peritoneal dialysis-lessons from a pharmacokinetic study.
Parminder K Judge, William G Herrington, Richard Haynes

Nephrol Dial Transplant· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The authors reply.
Daniel Chapman, Parminder K Judge, Thomas Arnold, Natalie Staplin, Sarah Clark

Kidney Int· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Daniel Chapman, Parminder K Judge, Rebecca J Sardell, Natalie Staplin, Thomas Arnold

Kidney Int· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.
Natalie Staplin, William G Herrington, Federico Murgia, Maysson Ibrahim, Katherine R Bull, Parminder K Judge

Hypertension· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Parminder K Judge, Richard Haynes

Curr Opin Nephrol Hypertens· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic kidney disease, heart failure and neprilysin inhibition.
Richard Haynes, Doreen Zhu, Parminder K Judge, William G Herrington, Philip A Kalra

Nephrol Dial Transplant· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
Richard Haynes, Parminder K Judge, Natalie Staplin, William G Herrington, Benjamin C Storey

Circulation· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biliary Tract and Liver Complications in Polycystic Kidney Disease.
Parminder K Judge, Charlie H S Harper, Benjamin C Storey, Richard Haynes, Martin J Wilcock

J Am Soc Nephrol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.
William Herrington, Natalie Staplin, Parminder K Judge, Marion Mafham, Jonathan Emberson

Hypertension· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis